Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial?

Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?

Cardiovascular (CV) disease is a major cause of morbidity and mortality in patients with diabetes. Whereas the link between glycemic control and reducing microvascular disease is firmly established, the evidence for macrovascular risk reduction remains unclear. Despite a host of available drugs for lowering serum glucose, none to date have been shown to substantially reduce CV risk and some hav...

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Risk in Patients with Diabetes: Fact or Fiction?

Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.

OBJECTIVE To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus. DESIGN Systematic review and meta-analysis of randomised controlled trials. DATA SOURCES Medline, Embase, the Cochrane Library, conference proceedings...

Dipeptidyl peptidase IV inhibitors and diabetes therapy.

Current type 2 diabetes therapies are mainly targeted at stimulating pancreatic beta-cell secretion and reducing insulin resistance. A number of alternative therapies are currently being developed to take advantage of the actions of the incretin hormones Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). These hormones are released from the small intestine i...

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures

OBJECTIVE Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far. RESEARCH DESIGN AND METHODS A meta-analysis was performed including all randomized clinical trials with a ...